Fortress Biotech Q3 net revenue $34.8M (up 100% QoQ); net loss narrows to $7.1M

Fortress Biotech, Inc.

2023-Q3 EPS reported -$7.94 revenue$64,567,000

Total consolidated net revenue $34.8M, including $19M upfront payment from Journey Medical's Maruho license.
Net loss attributable to common stockholders $7.1M ($0.94/share) vs $24.5M ($4.11) in Q3 2022.
Cash, equivalents and restricted cash $74.7M at Sept 30; subsequent public offering raised $10M in Nov 2023.
NDA for DFD-29 (rosacea) expected around year-end 2023; cosibelimab PDUFA date Jan 3, 2024.
Effected 1-for-15 reverse stock split in Oct 2023 to meet Nasdaq minimum bid price requirement.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Fortress Biotech, Inc. reported third quarter ended September 30, 2023 results: revenue $34.8 million.

Period: third quarter ended September 30, 2023
Revenue: $34.8 million
Result: reported results

Exact text from the filing

in such filing. --- EX-99.1 (EX-99.1) --- Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 Fortress is advancing several late-stage

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-019030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.